Stocky turns companies like SHIN NIPPON BIOMEDICAL LABORATO into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. 2395.T shows solid Growth Compounder strength (69/100) with respectable revenue expansion, but weak Leadership Alignment (45/100) and middling Value signals (58/100) raise concerns about capital discipline and founder conviction. At 15.1x forward earnings, the valuation is fair but not compelling enough to offset leadership red flags.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for SHIN NIPPON BIOMEDICAL LABORATO:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 59/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates SHIN NIPPON BIOMEDICAL LABORATO (2395.T) at 59/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. 2395.T shows solid Growth Compounder strength (69/100) with respectable revenue expansion, but weak Leadership Alignment (45/100) and middling Value signals (58/100) raise concerns about capital discipline and founder conviction.
2395.T's current Stocky Verdict is 59/100, placing it in the "Cautious" band. This composite combines a 69/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for SHIN NIPPON BIOMEDICAL LABORATO yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
SHIN NIPPON BIOMEDICAL LABORATO scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Vulnerability Profile for SHIN NIPPON BIOMEDICAL LABORATO covers customer concentration, supply chain risk, refinancing walls, and regulatory exposure. Not yet finalised.
Sign up free and unlock the full analysis on 2395.T — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 2395.T in the app.
